.Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04C_DrugsUsedInBenignProstaticHypertrophy.G04CB51_FinasterideAndTadalafil.FinasterideAndTadalafil .Pharmacolibrary.Drugs.G_GenitoUrinarySystemAndSexHormones.G04C_DrugsUsedInBenignProstaticHypertrophy.G04CB51_FinasterideAndTadalafil.FinasterideAndTadalafil| name: | FinasterideAndTadalafil |
| ATC code: | G04CB51 | route: | oral |
| n-compartments | 1 |
Finasteride and tadalafil is a fixed-dose combination medication used for the treatment of benign prostatic hyperplasia (BPH) in adult men. Finasteride is a 5α-reductase inhibitor that reduces prostatic volume by inhibiting the conversion of testosterone to dihydrotestosterone, while tadalafil is a phosphodiesterase type 5 (PDE5) inhibitor primarily used in erectile dysfunction and BPH to relax smooth muscle in the lower urinary tract. The combination is approved and marketed in several countries.
Estimated pharmacokinetic parameters in healthy adult males, since no published population pharmacokinetic model for the fixed-dose combination is available; separate parameters for finasteride and tadalafil monotherapy are known, estimates are provided for the combination.